PEPTOKING
EN

SURPASS-CVOT: tirzepatide matches dulaglutide on heart outcomes in type 2 diabetes

Trial result

Eli Lilly's SURPASS-CVOT trial randomized 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide (Mounjaro) or dulaglutide (Trulicity) and followed them for a median of four years. Tirzepatide met the non-inferiority goal, with 8% fewer major adverse cardiovascular events (hazard ratio 0.92, 95.3% CI 0.83 to 1.01), and all-cause death was 16% lower in an analysis not adjusted for multiple testing. More people stopped tirzepatide because of side effects (13.3% versus 10.2%).

Sources

  1. 01Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial(opens the source in a new tab) Eli Lilly and Company
  2. 02Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT(opens the source in a new tab) TCTMD

Peptides involved

  1. ApprovedTirzepatideDual GIP and GLP-1 receptor agonist39
  2. ApprovedDulaglutideGLP-1 receptor agonist (Fc fusion protein)31